Underwriting AgreementUnderwriting Agreement • September 1st, 2020 • Odonate Therapeutics, Inc. • Pharmaceutical preparations • New York
Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,614,036 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 842,105 additional shares (the “Optional Shares”) of common stock, par value $0.01 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares.”
